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tuberculosis mortality
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Abstract
Background: The Bacillus Calmette-Guérin (BCG) vaccine is provided to over 100 million neonates annually to
protect against childhood tuberculosis (TB). Recent BCG manufacturing interruptions highlight global supply risks.
We estimated the potential impact of BCG shortfalls on global paediatric (<15 years) TB mortality.
Methods: A static mathematical model was employed to estimate the number of paediatric TB deaths avoided by
usual levels of BCG coverage, and potential additional TB deaths in the first 15 years of life due to 1-year BCG
supply shortfalls of 6.3 % (as occurred in 2015) to 27.6 % (as anticipated without mitigating action in 2015)
assuming no catch-up campaigns.
Results: BCG coverage without shortfalls, estimated at 90 % globally, was estimated to avoid 117,132 (95 % uncertainty
range (UR): 5049–306,911) TB deaths globally per birth cohort in the first 15 years of life. An estimated 11,713
(UR: 505–30,691) additional TB deaths would occur in the first 15 years of life per 10 % (26 million dose) annual
supply shortfall. A 16.5 million dose (6.3 %) shortfall as reported at the close of 2015, reflecting 84 % global
coverage, was estimated as associated with 7433 (95 % UR: 320–19,477) excess TB deaths in the affected cohort
in the first 15 years. A possible 24,914 (UR: 1074–65,278) additional deaths were avoided due to prompt shortfall
reduction measures in 2015.
Conclusions: BCG shortages could greatly increase paediatric TB mortality. Although rapid action in 2015
minimised BCG shortfalls, avoiding a large number of potential additional deaths, the possible public health
impact of even relatively small shortfalls highlights the critical importance of ensuring secure future manufacturing
capacity and global BCG supply continuity.
Keywords: Bacillus Calmette-Guérin vaccine, Tuberculosis, Mycobacterium tuberculosis, Child, Paediatric, Mortality,
Shortage, Shortfall, Mathematical model
Background
As one of the earliest vaccines of the World Health
Organization’s (WHO) Expanded Program on Immu-
nization established in 1974, Bacillus Calmette-Guérin
(BCG) is a cornerstone of childhood vaccination. It is a
safe vaccine, used for neonatal vaccination in 84 % of
countries and provided to over 100 million neonates an-
nually to protect against childhood tuberculosis (TB) [1].
The vaccine is mostly supplied in 20-dose vials which
must be used within 6 hours of opening [2, 3]. Vaccine
wastage is therefore common, so annual global BCG
demand reaches approximately 260 million doses. Al-
most half of the global supply is procured through the
United Nations International Children’s Emergency Fund
(UNICEF). Historically, these volumes have been reliably
delivered [4], but sizeable shortfalls began in 2013 due to
technical production difficulties. A drop in supply was
experienced by both UNICEF and non-UNICEF markets,
leading to several, usually self-procuring, countries ap-
proaching UNICEF for access to BCG [4]. The shortfall
peaked at 22.8 million during 2014, and was 16.5 million
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at the end of 2015 [5, 6]. Current measures to ensure
BCG supply continuity are evidently insufficient.
It has been previously estimated that BCG averts one
case of meningeal TB in the first 5 years of life per 3435
vaccinated children and one case of miliary TB for every
9314 vaccinations [7], though this may vary substantially
by setting [8]. However, the impact of vaccination on TB
mortality and the potential public health consequences
of vaccine supply shortages have yet to be explored in
the published literature. Therefore, we have used mathe-
matical modelling to estimate the number of excess
paediatric (<15 years) TB deaths that could occur with
various BCG shortfall scenarios.
Methods
Data inputs and assumptions
Data inputs and sources are summarised in Table 1.
Our analysis assesses impact at the global level; there-
fore, where available, data employed are global esti-
mates. Although manufacturing difficulties began in
2013, shortages only began to outweigh mitigation
measures in 2014 [9]; therefore, 2013 data were used as
the no-shortfall baseline for model parameterisation.
The global BCG-eligible population was defined as the
annual birth cohort in countries with a policy of neonatal
BCG vaccination, identified as countries reporting BCG
coverage to WHO or neonatal vaccination policy in the
Global BCG Atlas [1, 10]. This was calculated from the
United Nations Population Division 2010–2015 birth
estimates [11], assuming equal distribution of births
across this period. Although BCG is contraindicated in
HIV-positive children [12], the denominator was not
adjusted as the proportion of the birth cohort for which
BCG is contraindicated due to HIV status is negligible [13].
UNICEF report global demand of 260 million BCG
doses per year [2, 6], with vaccination coverage esti-
mated at 90 % in 2013 [14]. BCG dose wastage at base-
line (w) was estimated at 54.7 %, in line with WHO-
UNICEF estimates [2], using current birth cohort (B),
annual BCG dose demand (D), and vaccine coverage
Covð Þ : w ¼ D− BCovð Þð ÞD :
We explored BCG supply shortfalls of 6.3 %, 10 %,
20 %, 27.6 %, and 100 % of the current 260 million dose
global demand; 6.3 % reflects the 16.5 million dose an-
nual supply shortfall at the end of 2015. At the height of
the most recent shortages, UNICEF anticipated shortfalls
of up to 71.8 million doses in 2015, equivalent to a
27.6 % shortfall on usual levels; 10 % and 20 % are hypo-
thetical shortfalls, of use for estimating impact of other
potential scenarios. A complete stockout (100 %) was
explored to estimate the impact of each year of BCG
vaccination. It was assumed that there would be no
catch-up campaign for children missing neonatal vaccin-
ation due to shortfalls, as BCG is not recommended for
children older than 12 months [15].
A meta-analysis of randomised controlled trials asses-
sing the rate ratio (RR) of TB death in BCG-vaccinated
versus BCG-unvaccinated neonates provided a pooled
random-effects estimate of 0.34 (95 % confidence inter-
val (CI), 0.12–0.92) [16]. Vaccine efficacy (VE) against
TB death is therefore calculated from this rate ratio
(VE = 1 – RR) as 66 % (95 % CI, 8–88 %). Similar esti-
mates were made by Colditz et al. [17] (VE 65 %, 95 % CI,
12–86 %) in a 1995 meta-analysis, but are superseded by
the Abubakar review [16]. The Mangtani et al. [18] review
does not explore vaccine impact on mortality, so cannot
be used for parameterisation of this model. The Abubakar
et al. [16] review estimates protection against TB death in
the overall population, as opposed to against death given
disease, therefore this was incorporated in the model as
the proportion of the vaccinated population with complete
protection against TB death.
Impact was explored over a 15-year time horizon, as
this is the WHO-defined reporting age for childhood
TB [19]. Data indicate that BCG provides at least
10 years of protection, and there is some indication of
protection still at or beyond 15 years [16, 20]. Therefore, it
is assumed that those vaccinated are protected for the 15-
year model time horizon. There is no clear evidence to
parameterise vaccine waning during this period, so no
waning is assumed.
As BCG is contraindicated in HIV-positive neonates
[12], and more than 90 % of paediatric HIV infections
have been attributed to mother-to-child transmission [21],
it is assumed that the vast majority of HIV-positive paedi-
atric TB deaths are not BCG-preventable. Therefore, we
Table 1 Data inputs and model assumptions
Variable (symbol) Point estimate (range) Source
Population at risk
Annual global BCG-eligible
birth cohort (B)
130.8 million [1, 10, 11]
Population vaccinated HIV-negative [12]
HIV-negative paediatric TB
deaths in 2013 (Mort)
80,000 (64,000–97,000) [19]
Vaccine deployment
Annual BCG demand (D) 260 million [2, 6]
BCG coverage in 2013 (Cov) 90 % [14]
Vaccine characteristics
Vaccine efficacy against
TB death (VE)
66 % (8–88 %) [16, 17]
Duration of protection 15 years [16]
Waning of protection None Assumption
Catch-up campaign None Assumption
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assume that only HIV-negative paediatric mortality is
potentially vaccine preventable (Table 1) [19]. As has
been assumed in other BCG modelling studies [8],
the annual paediatric TB mortality (‘period mortality’)
is assumed to be equivalent to the number of deaths
in a 1-year birth cohort over the first 15 years of life
(‘cohort mortality’). It is implicit in this assumption
that there would be no change in the risk of infection
or mortality rates during the 15-year model time
horizon.
Model
A static mathematical model was developed in Micro-
soft Excel® (2013) to estimate the risk of TB death in
the first 15 years of life in unprotected infants, the
number of paediatric TB deaths in the first 15 years
of life avoided by usual levels of BCG coverage, and the
potential number of additional deaths due to 1 year of
BCG shortfalls of between 6.3 % and 27.6 % of current
global demand.
To estimate the individual-level risk of TB death in
the first 15 years of life for children not protected by
the vaccine, the number of unprotected children (n)
in the birth cohort (B) was first estimated. Those not
protected include unvaccinated children and vacci-
nated children with insufficient immune response for
protection.
n ¼ B  1−Covð Þ þ B  Cov  1−VEð Þ ð1Þ
The risk of TB death in the first 15 years of life for un-
protected children (uTB) was then calculated by dividing
the baseline number of TB deaths (Mort) by the number
of unprotected children:
uTB ¼ Mortn ð2Þ
For each of the shortfall scenarios (s = 6.3 %, 10 %,
20 %, 27.6 %, 100 %), the number of available doses (ds)
and vaccine wastage (w) were employed to calculate vac-
cine coverage (Covs) of the birth cohort:
Covs ¼ ds  1−wð ÞB ð3Þ
The number of children unprotected (ns) was calcu-
lated for each scenario using Covs in equation 1. These
were used to estimate the number of additional deaths
(As) for each scenario expected in one birth cohort in
the first 15 years of life:
As ¼ uTB  nsð Þ−Mort ð4Þ
Uncertainty analysis
Uncertainty was estimated by sampling values of paediatric
TB mortality and the rate ratio of TB death in vaccinated
versus unvaccinated neonates (used to calculate vaccine
efficacy) [16, 19]. The underlying distribution of the TB
mortality estimates is not published; therefore, a log-
normal distribution was generated from the point estimate
(80,000) and 95 % range (64,000–97,000) [19]. A log-
normal distribution was also employed for the rate ratio, as
the published confidence intervals were estimated using the
DerSimonian and Laird method [16, 22]. Location and scale
parameters for both distributions were estimated using the
2.5 %, 50 % and 97.5 % quantiles in the rriskDistribu-
tions package in the statistical programme R [23, 24].
A total of 100,000 parameter sets and model outputs
were generated according to the prior-defined probabili-
ties using Oracle® Crystal Ball (release 11.1.2.4.400, Oracle
Corporation, USA). Median and 95 % uncertainty ranges
for each estimate were calculated from the 100,000 model
outputs.
Results
It is estimated that one year of global BCG vaccination at
usual levels of coverage (90 %) averts 117,132 (95 % UR:
5049–306,911) TB deaths during the first 15 years of life
of that cohort (Table 2). Therefore, without BCG, the
point estimate of annual HIV-negative paediatric TB mor-
tality would be estimated to increase from 80,000 to ap-
proximately 197,100. The wide uncertainty ranges derive
from the wide confidence intervals around the pooled esti-
mate of the rate ratio of TB death in BCG-vaccinated
Table 2 Estimated additional paediatric TB deaths in BCG supply shortfall scenarios
Supply shortfall (%) Number of doses
shortfall (million)
Global BCG
coverage (%)
Estimated number of additional paediatric TB deaths
in a 1 year cohort in the first 15 years of life
Increase in number
of deaths (%)
Median 95 % Uncertainty Range
6.3 16.5 84 7433 320–19,477 9.3
10 26 81 11,713 505–30,691 14.6
20 52 72 23,426 1010–61,382 29.3
27.6 71.8 65 32,347 1394–84,755 40.4
100 260 0 117,132 5049–306,911 146.4
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versus BCG-unvaccinated neonates, as a limited number
of studies with relatively small sample sizes from different
settings contribute to meta-analyses of this parameter. In
our main analysis, it was assumed that the rate ratio of TB
death by vaccination status and the global estimate of
paediatric TB deaths were uncorrelated and were thus
sampled independently. As some correlation may exist, a
post-hoc analysis assessing the sensitivity of the results to
correlation assumptions was conducted. Even in the most
extreme scenario of 100 % correlation between these two
variables, uncertainty ranges around the annual number
of TB deaths averted at 2013 vaccination levels narrowed
only marginally to 5781–244,556.
The hypothetical scenarios explored suggest approxi-
mately an additional 11,713 (95 % UR: 505–30,691)
paediatric TB deaths in a 1-year cohort in the first
15 years of life per 10 %, or 26 million dose, BCG short-
fall. This is a 14.6 % increase in the number of deaths.
A 16.5 million dose (6.3 %) shortfall as reported at the
close of 2015, which is reflective of 84 % global coverage,
would be estimated to be associated with 7433 (95 % UR:
320–19,477) excess TB deaths in the affected birth cohort
in the first 15 years of life (Table 2). A 27.6 % shortfall on
global demand was estimated to be associated with 32,347
(95 % UR: 1394–84,755) additional deaths. Therefore,
measures to reduce the shortfall from the anticipated
27.6 % to 6.3 % are estimated to have avoided a possible
24,914 (UR: 1074–65,278) additional deaths.
The modelled estimate of the risk of TB death for an un-
protected child in the first 15 years of life (uTB) was 0.00151
(95 % UR: 0.00064–0.00299), otherwise expressed as 151
(64–299) per 100,000 children in the first 15 years of life.
Discussion
Given historical security in BCG supply, the potential pub-
lic health impact of shortfalls has not previously been quan-
tified. The static mathematical cohort model presented
here indicates that even relatively small BCG supply short-
falls could cause sizeable increases in paediatric mortality in
the affected cohorts. It is estimated that current coverage of
BCG prevents 117,132 (95 % UR: 5049–306,911) paediatric
TB deaths in the first 15 years of life per birth cohort, sug-
gesting that an additional 11,713 (95 % UR: 505–30,691)
paediatric deaths could be expected per 10 %, or 26 million
dose, annual shortfall in BCG supply. Therefore, in the
worst case scenario of a 71.8 million dose shortfall antici-
pated by UNICEF in 2015, up to an additional 32,347 (95 %
UR: 1394–84,755) paediatric TB deaths could have been ex-
pected in the affected cohort over the 15-year time horizon.
However, measures minimising the 2015 shortfall to 16.5
million reduced the estimated number of additional deaths
to 7433 (95 % UR: 320–19,477).
UNICEF procures WHO-prequalified (PQ) BCG from
five manufacturers. Adjusting quantities awarded to
these manufacturers can meet small-scale changes in
demand. However, this supply chain is relatively unre-
sponsive to rapid, or large, changes in supply or demand.
In recent years, insufficient supply in the non-UNICEF
BCG market has inflated demand for UNICEF-procured
PQ vaccine from usually self-procuring countries, such
as Egypt, Philippines, Pakistan, and South Africa [6, 25].
Thus, the UNICEF market is vulnerable to challenges
faced by any manufacturer, not just those supplying PQ
vaccine. During the same period, manufacturing short-
falls were also experienced by two PQ vaccine suppliers
[4, 6]. These concurrent changes in supply and demand
for PQ vaccine far exceeded the responsiveness of the
supply system, leading to unmet demand [6].
Rapid and coordinated action from multiple stake-
holders to increase supply and to hold buffer stocks at
the global rather than national level to allow for priori-
tisation of limited stocks to high TB-burden countries
reduced projected BCG shortages from potentially 71.8
million down to 16.5 million at the end of 2015 [5, 6].
The laudable efforts by multiple stakeholders to minim-
ise BCG shortfalls averted an estimated 24,914 (UR:
1074–65,278) additional paediatric deaths. However, due
to the remaining shortfall at the close of 2015, it is esti-
mated that a possible 7433 (95 % UR: 320–19,477) addi-
tional paediatric TB deaths could be expected in the first
15 years of life of the birth cohort affected in 2015 alone.
Therefore, although rapid action in 2015 minimised
shortfalls, avoiding a large number of potential addi-
tional deaths, the estimated public health impact of
even such a relatively small shortfall highlights the im-
portance of ensuring secure manufacturing capacity to
meet global BCG demand.
In the estimates presented, the impact of only one
year of shortfall was considered, yet recent shortfalls
have already extended over several years. Such short-
ages affecting multiple birth cohorts would result in
even greater public health impact. Resolution of the
underlying causes takes time; therefore, strategies to
pre-emptively avoid shortfalls are essential to avoid un-
necessary childhood illness and deaths from TB. New
BCG suppliers have been assessed for pre-qualification
to increase availability, but future risks include an an-
ticipated 30 % rise in the BCG weighted average price,
the sale of one of the UNICEF suppliers making future
production plans uncertain, and on-going supply short-
ages [5, 6]. It appears unlikely that new manufacturers
will enter the market, and there are no known plans for
existing suppliers to expand their facilities; therefore,
with fixed suppliers and production capacity, mass pro-
duction of such biologicals will continue to suffer from
the small, but very real, risk of production delays.
Reducing vaccine wastage from 20-dose vials could help
maximise utilisation of available vaccines. Our model
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estimates 54.7 % dose wastage, aligning with the WHO/
UNICEF-estimated wastage of approximately 50 % [2].
Wastage is particularly prevalent in smaller health centres,
where insufficient neonates present for vaccination during
the 6-hour vial use window. Economic modelling has
demonstrated that clinics vaccinating fewer than seven
infants daily would likely benefit from a 10-dose format
[26]. It is also believed that availability of smaller vials
would be associated with increased willingness to open
vials to provide timely vaccination and increased coverage.
Therefore, production of both 10- and 20-dose vials for
infant vaccination could allow tailoring of supply by
setting, reducing wastage, increasing coverage and po-
tentially reducing the risk of shortages.
Another, longer-term solution to BCG supply issues
could be implementation of a more time- and cost-efficient
manufacturing process. Current BCG supplies are manu-
factured by the labour-intensive, classic surface growth
method, but a more modern, cost-efficient, dispersed,
liquid fermentation process currently in use for novel
BCG replacement candidates could potentially provide
a more consistent product if used in BCG production
and could help ensure adequate global supplies (Personal
communication, Ann Ginsberg, Aeras, January 20th 2016).
Mathematical models are, by definition, a simplifica-
tion of reality. Some specific limitations of this approach
are considered. As paediatric cases are generally minim-
ally infectious [27], a static cohort model assuming no
transmission nor indirect vaccine effects was employed.
This limitation may produce an underestimate of the
impact of vaccine shortages on TB mortality. The WHO
estimate of HIV-negative childhood TB mortality is a
key input in this analysis, yet methodology for estima-
tion of paediatric disease burden is evolving, and there-
fore the size of the estimates may change in coming
years. However, such changes do not affect the propor-
tional increase in the number of deaths expected in each
scenario, and therefore the impact of shortfalls could be
re-estimated in the future using the proportions re-
ported in Table 2. If countries are contributing cases but
are excluded from the denominator due to not having a
policy of neonatal BCG vaccination, the model could
marginally overestimate the effect of the intervention.
However, this is expected to be minimal given paediatric
TB is generally a sentinel of high transmission, and in
such settings BCG is usually offered.
Uncertainty ranges around the modelled estimates are
wide due to large confidence intervals around the vac-
cine efficacy parameter derived from the Abubakar et al.
[16] meta-analysis. Factors contributing to this uncer-
tainty include heterogeneity between study settings and
the small number of studies included in the meta-
analysis (n = 5), with relatively low numbers of person
years accrued and very few mortality endpoints. All of
the studies were conducted between 1933 and 1960.
New research could help improve the body of evidence
for this parameter, and therefore improve modelled esti-
mates of BCG impact. Placebo controlled trials of BCG
are no longer ethical due to lack of equipoise, and retro-
spective observational designs often suffer from substan-
tial biases, but prospective observational studies with
larger sample sizes could potentially contribute to the
evidence base for this parameter.
It is possible that some HIV-positive TB mortality
may be BCG-preventable, as some healthy HIV-positive
neonates with unknown HIV status may be vaccinated,
and some children become HIV-infected after receipt
of BCG. BCG efficacy against mortality is unknown in
these groups, but if BCG were to provide partial protec-
tion in these children, the reported impact of BCG
shortages would be an underestimate.
Although data are limited, it is possible that BCG pro-
tection could wane or the duration of protection could
be shorter than the modelled period, and therefore the
assumption of 15 years of full protection could produce
an overestimate of the impact of shortfalls. Conversely,
protection is also likely to continue to prevent deaths
beyond 15 years of age, but such longer-term impact
was outside the scope of this research question.
There is an increasing body of evidence suggestive of a
potentially important non-specific beneficial effect of
BCG vaccination against all-cause mortality [28]. Con-
trolled trials and observational evidence from the USA,
UK and West African settings have reported point esti-
mates of 25–60 % reduction in all-cause mortality, with
impact particularly pronounced in the neonatal period
[28, 29]. Therefore, the number of all-cause deaths may
also increase with BCG shortfalls, but such non-specific
vaccine effects are not accounted for in the model.
It is assumed in the model that neonates missed due
to 1-year BCG shortfalls would not receive catch-up vac-
cination, as WHO does not recommend vaccination
above 12 months of age and catch-up campaigns may be
difficult to implement [15]. However, for infants under
12 months when supply is restored, catch-up doses may
be given to some infants concomitant with other routine
Expanded Program on Immunization vaccines, poten-
tially reducing the impact of shortfalls.
UNICEF-reported shortfalls account for demand due to
basic country needs and likely some over-procurement to
replenish buffer stocks [6]. The scale of over-procurement
is unknown and therefore could not be accounted for, but
may cause some overestimate of impact in the 2015 sce-
narios. There are also insufficient data available to quan-
tify the possible mitigating effects of existing buffer stocks
in the model. However, in 2014, 28 countries reported
BCG stockouts of at least a month at the national level, of
which 86 % reported interruption of BCG vaccination
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services [30]; therefore, country reports clearly support
the model assumption that global BCG shortages lead to
programmatic vaccine shortages.
This global-level model using a single pooled estimate
of vaccine efficacy cannot account for likely heterogeneity
in the location of stockouts and possible latitudinal vari-
ation in vaccine efficacy [16, 18]. A regional- or country-
level model would have been desirable, but estimates of
country- or regional-level burden of paediatric TB mor-
tality have not yet been published. When supply short-
falls occur, available UNICEF-procured vaccines are
prioritised to high TB burden countries [25, 31]. This
could not be accounted for in the model due to the lack
of the required mortality burden estimates to develop a
country-level model, and there are also no data avail-
able on how BCG was distributed. Differential distribu-
tion of stock could therefore not be accounted for in
this global-level model, and thus may overestimate the
impact of shortfalls if high burden countries experience
fewer shortfalls. However, this mitigation mechanism
does not guarantee supply, especially when the global
demand gap is large, as demonstrated in 2014 when six
of the 22 WHO high-burden countries reported an
interruption of vaccination services [30]. This limitation
also highlights the importance of UNICEF-led BCG pro-
curement, as left to market forces alone it is likely that
many high-burden countries would struggle to procure
sufficient vaccine.
Conclusion
BCG is a mainstay of neonatal vaccination, yet the risks
of supply shortages have not previously been explored.
It is clear that even relatively small shortfalls have the
potential to cause a considerable number of additional
paediatric TB deaths, and the public health risks of
larger shortfalls are immense. This is a current issue of
global relevance; therefore, continued mobilization to
eliminate current shortfalls and development of a se-
cure and responsive mechanism of supply to adequately
meet future global demand should be a global public
health priority.
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